Edward Nash
Stock Analyst at Canaccord Genuity
(4.51)
# 289
Out of 4,981 analysts
88
Total ratings
54.55%
Success rate
24.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $428 → $526 | $425.60 | +23.59% | 11 | Sep 12, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $137 → $140 | $69.53 | +101.35% | 9 | Sep 10, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $64 → $62 | $24.50 | +153.06% | 2 | Aug 20, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $28 | $6.36 | +340.25% | 1 | Jul 24, 2025 | |
| VRNA Verona Pharma | Downgrades: Hold | $107 | $106.37 | +0.59% | 10 | Jul 9, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $23.01 | +104.26% | 10 | Apr 10, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $0.49 | +1,744.64% | 2 | Feb 26, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Hold | $4 | $1.53 | +161.44% | 2 | Feb 10, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $56 → $73 | $42.85 | +70.36% | 6 | Jan 28, 2025 | |
| APGE Apogee Therapeutics | Initiates: Buy | $89 | $36.86 | +141.45% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $14 | $2.30 | +508.70% | 6 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.08 | +640.74% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $20 | $5.31 | +276.65% | 2 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $8 | $3.29 | +143.16% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $7.47 | +127.58% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.36 | -15.25% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $1.46 | +12,228.77% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $29.00 | +182.76% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $3.07 | +2,505.86% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $14.84 | +223.56% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.73 | +11,253.71% | 1 | Nov 8, 2017 |
Madrigal Pharmaceuticals
Sep 12, 2025
Maintains: Buy
Price Target: $428 → $526
Current: $425.60
Upside: +23.59%
Corcept Therapeutics
Sep 10, 2025
Maintains: Buy
Price Target: $137 → $140
Current: $69.53
Upside: +101.35%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $64 → $62
Current: $24.50
Upside: +153.06%
Sagimet Biosciences
Jul 24, 2025
Initiates: Buy
Price Target: $28
Current: $6.36
Upside: +340.25%
Verona Pharma
Jul 9, 2025
Downgrades: Hold
Price Target: $107
Current: $106.37
Upside: +0.59%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $23.01
Upside: +104.26%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $0.49
Upside: +1,744.64%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.53
Upside: +161.44%
Akero Therapeutics
Jan 28, 2025
Maintains: Buy
Price Target: $56 → $73
Current: $42.85
Upside: +70.36%
Apogee Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $36.86
Upside: +141.45%
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $2.30
Upside: +508.70%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.08
Upside: +640.74%
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $5.31
Upside: +276.65%
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $3.29
Upside: +143.16%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $7.47
Upside: +127.58%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.36
Upside: -15.25%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $1.46
Upside: +12,228.77%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $29.00
Upside: +182.76%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $3.07
Upside: +2,505.86%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $14.84
Upside: +223.56%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.73
Upside: +11,253.71%